Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: An open-label, multicentre, randomised, phase 3 trial

The Lancet Oncology

Volumn 16, Issue 15, 2015, Pages 1525-1536

  Rambaldi, Alessandro ^a   Grassi, Anna ^a   Masciulli, Arianna ^b   Boschini, Cristina ^a   Micò, Maria Caterina ^a   Busca, Alessandro ^c   Bruno, Benedetto ^c   Cavattoni, Irene ^d   Santarone, Stella ^e   Raimondi, Roberto ^f   Montanari, Mauro ^g   Milone, Giuseppe ^h   Chiusolo, Patrizia ⁱ   Pastore, Domenico ^j   Guidi, Stefano ^k   Patriarca, Francesca ^l   Risitano, Antonio M ^m   Saporiti, Giorgia ⁿ   Pini, Massimo ^o   Terruzzi, Elisabetta ^p   Arcese, William ^q   Marotta, Giuseppe ^r   Carella, Angelo Michele ^s   Nagler, Arnon ^t   Russo, Domenico ^u   Corradini, Paolo ^v   Alessandrino, Emilio Paolo ^w   Torelli, Giovanni Fernando ^x   Scimè, Rosanna ^y   Mordini, Nicola ^z   Oldani, Elena ^a   Marfisi, Rosa Maria ^b   Bacigalupo, Andrea ^aa   Bosi, Alberto ^k   more..

^a Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d CENTRAL HOSPITAL OF BOLZANO   (Italy)

^e SPIRITO SANTO HOSPITAL   (Italy)

^f SAN BORTOLO HOSPITAL   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^j UNIVERSITY OF BARI   (Italy)

^k UNIVERSITY OF FLORENCE   (Italy)

^l SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^m FEDERICO II UNIVERSITY HOSPITAL   (Italy)

ⁿ UNIVERSITY OF MILAN   (Italy)

^o H SS Antonio e Biagio   (Italy)

^p SAN GERARDO HOSPITAL   (Italy)

^q TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^r UNIVERSITY HOSPITAL OF SIENA   (Italy)

^s CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^t SHEBA MEDICAL CENTER   (Israel)

^u UNIVERSITY OF BRESCIA   (Italy)

^v NATIONAL CANCER INSTITUTE   (Italy)

^w FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^x SAPIENZA UNIVERSITY OF ROME   (Italy)

^y Bone Marrow Transplantation Unit   (Italy)

^z S CROCE E CARLE HOSPITAL   (Italy)

^aa UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; METHOTREXATE; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; VIDARABINE;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALLERGY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BLADDER DISEASE; BLEEDING; BLOOD CLOTTING; BONE MARROW DISEASE; CANCER MORTALITY; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM DISEASE; CONTROLLED STUDY; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HEART DISEASE; HEMATOLOGIC DISEASE; HEPATOBILIARY DISEASE; HUMAN; IMMUNOPATHOLOGY; INFECTION; KIDNEY DISEASE; LABORATORY TEST; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; METASTASIS; MUCOSAL DISEASE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MUSCULOSKELETAL DISEASE; MYCOSIS; MYELOABLATIVE CONDITIONING; NEUROLOGIC DISEASE; OPEN STUDY; PAIN; PANCREAS DISEASE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SIDE EFFECT; SKIN DISEASE; SOFT TISSUE DISEASE; STOMACH DISEASE; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; VIRUS INFECTION; VISUAL DISORDER; ALLOTRANSPLANTATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 84955262893     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00200-4     Document Type: Article

References (30)

1. Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
2. Cornelissen JJ, Gratwohl A, Schlenk RF, et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nat Rev Clin Oncol 2012, 9:579-590.
3. Shouval R, Labopin M, Unger R, et al. Prediction of allogeneic HSCT related mortality in acute leukemia: exploring boundaries of prediction through machine learning based modeling: a data mining study from the Acute Leukemia Working Party (ALWP) of the EBMT. 56th ASH Annual Meeting and Exposition; San Francisco, CA; Dec 6-9, 2014. Abstract 2568.
4. Nagler A, Rocha V, Labopin M, et al. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen-a report from the acute leukemia working party of the European group for blood and marrow transplantation. J Clin Oncol 2013, 31:3549-3556.
5. Bredeson C, LeRademacher J, Kato K, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 2013, 122:3871-3878.
6. Copelan EA, Hamilton BK, Avalos B, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood 2013, 122:3863-3870.
7. Cornelissen JJ, van Putten WL, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 2007, 109:3658-3666.
8. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997, 89:4531-4536.
9. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998, 91:756-763.
10. Shimoni A, Nagler A Allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia in first complete remission: new answers for an old question. Leukemia 2005, 19:891-893.
11. Blaise D, Vey N, Faucher C, Mohty M Current status of reduced intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica 2007, 92:533-541.
12. de Lima M, Couriel D, Thall PF, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004, 104:857-864.
13. Andersson BS, de Lima M, Thall PF, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant 2008, 14:672-684.
14. Chae YS, Sohn SK, Kim JG, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant 2007, 40:541-547.
15. Bredeson CN, Zhang MJ, Agovi MA, et al. Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:993-1003.
16. Lee JH, Joo YD, Kim H, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol 2012, 31:701-709.
17. Liu H, Zhai X, Song Z, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol 2013, 6:15.
18. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988, 6:1562-1568.
19. Fine JP, Gray RJ A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
20. Raimondi R, Tosetto A, Oneto R, et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study. Blood 2012, 120:1327-1333.
21. Alatrash G, de Lima M, Hamerschlak N, et al. Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 2011, 17:1490-1496.
22. Cornelissen JJ, Versluis J, Passweg JR, et al. Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia 2015, 29:1041-1050.
23. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012, 119:3908-3916.
24. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002, 8:493-500.
25. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood 2004, 104:865-872.
26. Alyea EP, Kim HT, Ho V, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005, 105:1810-1814.
27. Martino R, de Wreede L, Fiocco M, et al. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT. Bone Marrow Transplant 2013, 48:761-770.
28. Bornhauser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012, 13:1035-1044.
29. Forman SJ What is the role of reduced-intensity transplantation in the treatment of older patients with AML?. Hematology Am Soc Hematol Educ Program 2009, 2009:406-413.
30. Craddock C Pharmacological methods to reduce disease recurrence. Hematology Am Soc Hematol Educ Program 2013, 2013:63-69.